ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Olanzapine

Also written as “olanzapine”, “ALKS 3831” and “Olanzapine Tablets 5 mg”.

Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Treatment-Resistant · Fasting · Borderline Personality Disorder, led by 11 companies.

Drug pageOlanzapine: every studyMany companies study it; this page follows only the 54 they lead. All 266 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 30, 200254 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly360 open or runningphase 4since Apr 30, 2002Apr 30, 2002none ahead
Viatrisits history only50 open or runningphase 4since Oct 12, 2005Sep 1, 2005none ahead
Dr. Reddy's Laboratoriesits history only40 open or runningphase 1since Jan 2, 2012Jan 2, 2012none ahead
Abbottits history only20 open or runningphase 4since Oct 16, 2003Oct 16, 2003none ahead
AstraZenecaits history only10 open or runningphase 3since May 2, 2002May 2, 2002none ahead
HK inno.Nits history only10 open or runningphase 4since May 11, 2014May 11, 2014none ahead
Joint Stock Company "Farmak"its history only10 open or runningphase 1since Nov 15, 2021Nov 15, 2021none ahead
Neurelisits history only10 open or runningphase 1since Sep 6, 2024Sep 6, 2024none ahead
Orexigen Therapeuticsits history only10 open or runningphase 2since Aug 12, 2008Aug 12, 2008none ahead
Qilu Pharmaceuticalits history only10 open or runningphase 3since Mar 27, 2023Mar 27, 2023none ahead

Also a collaborator on its studies: Pfizer and H. Lundbeck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 22 studies since Apr 30, 2002.

  1. Nov 28, 2005Phase 3 study in Bipolar Disorder I or IINCT00259272 · 141 enrolled · France
  2. Dec 15, 2005Phase 3 study in ManiaNCT00266630 · 139 enrolled · Japan
  3. Mar 15, 2006Phase 4 study in SchizophreniaNCT00303602 · 149 enrolled · United States, Canada, Mexico and more
  4. Jun 14, 2006Phase 4 study in SchizophreniaNCT00337662 · 628 enrolled · United States, Argentina, Russian Federation
  5. Nov 17, 2006Phase 4 study in Bipolar I DisorderNCT00402324 · 202 enrolled · United States
  6. Nov 17, 2006Phase 3 study in SchizophreniaNCT00401973 · 199 enrolled · United States, Brazil, Israel and more
  7. Jun 11, 2007Phase 4 study in Bipolar DisorderNCT00485771 · 403 enrolled · United States
  8. Jul 30, 2007Phase 3 study in Bipolar DisorderNCT00510146 · 514 enrolled · China, Japan, Korea, Republic of
  9. Feb 8, 2008Phase 3 study in Bipolar I DisorderNCT00618748 · 101 enrolled · Japan
  10. Mar 18, 2008Phase 3 study in SchizophreniaNCT00640510 · 34 enrolled · Japan
  11. Oct 3, 2008Phase 4 study in Bipolar DisorderNCT00767715 · 11 enrolled · Sweden
  12. Aug 12, 2009Phase 3 study in Depressive Disorder, Treatment-ResistantNCT00958568 · 892 enrolled · United States, Argentina, India and more
  13. Sep 1, 2009Phase 3 study in SchizophreniaNCT00970281 · 91 enrolled · Japan
  14. Sep 7, 2012Phase 3 study in Depressive Disorder, Treatment-ResistantNCT01687478 · 176 enrolled · China

TargetBeta

“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule

Studies

All 36 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01687478Depressive Disorder, Treatment-Resistant · China3TerminatedNov 2015176
NCT00970281Schizophrenia · Japan3CompletedApr 201191
NCT00958568Depressive Disorder, Treatment-Resistant · United States, Argentina, India and more3CompletedMar 2012892
NCT00767715Bipolar Disorder · Sweden4TerminatedApr 200511
NCT00640510Schizophrenia · Japan3CompletedJul 200834
NCT00618748Bipolar I Disorder · Japan3CompletedSep 2010101
NCT00510146Bipolar Disorder · China, Japan, Korea, Republic of3CompletedMar 2010514
NCT00485771Bipolar Disorder · United States4Completed403
NCT00402324Bipolar I Disorder · United States4CompletedFeb 2008202
NCT00401973Schizophrenia · United States, Brazil, Israel and more3CompletedSep 2008199
NCT00337662Schizophrenia · United States, Argentina, Russian Federation4CompletedDec 2007628
NCT00303602Schizophrenia · United States, Canada, Mexico and more4CompletedDec 2007149
NCT00266630Mania · Japan3CompletedMay 2009139
NCT00259272Bipolar Disorder I or II · France3CompletedMay 2008141
NCT00191997Bipolar Disorder · Spain4Completed180
NCT00191828Weight Gain · Italy4Completed60
NCT00191555Schizophrenia · France4Completed360
NCT00190892Bipolar Disorder · Australia, Greece, Hungary and more4Completed120
NCT00190749Schizophrenia · United States4CompletedJun 2008130
NCT00129220Bipolar Disorder · Japan3CompletedJan 2009224
NCT00113594Schizophrenia · United States, Puerto Rico, Russian Federation3Completed100
NCT00103571Schizophrenia · United States, Puerto Rico4Completed600
NCT00100776Schizophrenia · United States4Completed600
NCT00094549Bipolar Disorder · United States, Lithuania, Puerto Rico and more4Completed500
NCT00091650Borderline Personality Disorder · United States, Belgium, France and more3Completed300
NCT00090012Schizophrenia · United States4Completed340
NCT00088491Schizophrenia · Finland, Turkey3Completed1,205
NCT00088465Schizophrenia · United States, Argentina, Australia and more3CompletedDec 2010931
NCT00088049Schizophrenia · United States4Completed560
NCT00088036Borderline Personality Disorder · United States, Argentina, Poland and more3Completed450
NCT00051298Schizophrenia · United States, Russian Federation3Completed107
NCT00050206Bipolar Disorder · United States4Completed130
NCT00036088Schizophrenia · United States, Argentina, Austria and more4Completed530
NCT00035321Depressive Disorder, Major · United States, Canada3Completed600
NCT00034801Depression · United States4Completed378
NCT00034580Bipolar Disorder · United States4Completed326

How it is read

Names in the registry

  • “Olanzapine”, 33 entries
  • “olanzapine”, 17 entries
  • “ALKS 3831”, 7 entries
  • “Olanzapine Tablets 5 mg”, 2 entries
  • “Olanzapine OD Tablets 5 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.